Key takeaways
- Dapoxetine is an on-demand treatment for diagnosed premature ejaculation, rather than a daily antidepressant treatment. Irish Priligy prescribing information.
- The clinical problem includes poor control and distress, not simply falling short of an imagined ideal duration. HPRA product information.
- Nausea, dizziness and fainting can occur. The product information advises avoiding alcohol. Priligy safety information.
- A trial found benefit in selected men also receiving erectile-dysfunction treatment, but that does not override the label’s warning against combining Priligy with PDE5 inhibitors. Combination trial, HPRA prescribing information.
In the cited trial, 56.5% of men taking dapoxetine rated their premature ejaculation at least “better”, compared with 35.4% taking placebo. The researchers also used a stopwatch and asked about control and distress. A longer interval was only one measure of benefit. Trial outcomes.
Dapoxetine, associated with Priligy and catalogue brands such as Poxet, is a premature-ejaculation treatment. It does not treat erection firmness or guarantee a particular performance.
What can dapoxetine improve?
Trials assess time to ejaculation, perceived control and distress, rather than a single target duration.
The Irish Priligy authorisation is for men aged 18 to 64 who meet its diagnostic criteria for premature ejaculation. It is not intended for men without that diagnosis who simply want to delay ejaculation. The clinical assessment also considers whether the problem is longstanding or new and whether erection difficulties are involved. HPRA-authorised medicine information.
The randomised trial enrolled 495 men with both premature ejaculation and erectile dysfunction; 429 completed the 12-week study. Average stopwatch-measured time at the end was 5.2 minutes with dapoxetine and 3.4 minutes with placebo. The men were already using a stable PDE5-inhibitor regimen. Entry required ejaculation within 2 minutes in at least 75% of intercourse episodes, among other criteria, so these averages cannot be applied to every man considering treatment. Combination trial.
How is on-demand treatment different from daily antidepressants?
Dapoxetine is used around anticipated sexual activity, with a slower elimination phase after its initial rapid fall in blood concentration.
The Irish product information gives an initial half-life of about 1.5 hours and a terminal half-life of about 19 hours. By 24 hours, the blood concentration is below 5% of its peak. That is a concentration comparison, not proof that the medicine has completely left the body. Interactions and sexual side effects remain possible. Priligy pharmacology and adverse effects.
European urology guidance also discusses topical anaesthetics, off-label antidepressants and psychosexual approaches. Treatment can address distress and communication as well as ejaculation timing. These are options to compare, not medicines to combine independently. EAU guideline.
Do not add dapoxetine to an existing antidepressant regimen because both medicines appear under “SSRIs”. Our vortioxetine article discusses sexual function in the different context of depression treatment.
| What you want to improve | What needs checking |
|---|---|
| Ejaculation control | Whether the symptoms fit premature ejaculation |
| Erection firmness | Whether erectile dysfunction needs its own assessment |
| Treatment-related sexual problems | Whether an existing medicine is contributing |
| Comfort and confidence | Whether psychosexual or relationship support could help alongside treatment |
Can dapoxetine be combined with sildenafil or tadalafil?
Do not assume a positive trial makes the combination suitable for self-treatment.
In the selected-patient trial, adverse events occurred in 29.6% with dapoxetine and 20.0% with placebo. In both groups, 1.6% stopped because of adverse events. The Irish Priligy prescribing information advises against use in men with erectile dysfunction taking PDE5 inhibitors, because of concerns about reduced tolerance to standing-related blood-pressure changes. Trial, HPRA warning.
The EAU guideline discusses trials of dapoxetine with PDE5 inhibitors, including sildenafil, and reports benefits in selected patients. The Irish Priligy label still says it should not be used by men taking PDE5 inhibitors. Its concern is orthostatic tolerance, meaning the body’s response when standing. The clinician has to reconcile that product warning with the study population and the individual’s history. A favourable trial does not cancel the warning or justify trying the combination yourself. EAU treatment recommendations.
Which risks should be discussed before treatment?
Fainting history, heart disease and interactions are particularly important.
Other antidepressants, MAO inhibitors, tramadol and serotonergic supplements such as St John’s wort can create serious interaction risks. Alcohol increases concern about dizziness, impaired judgement and fainting. If you become light-headed, sit or lie down safely; do not drive while affected. Priligy warnings.
A newly developed sexual problem can also merit a broader assessment. Our prolactin article discusses one specific hormonal condition, not a reason for routine hormone treatment or testing in everyone with premature ejaculation.
Do and don’t
Do:
- Describe control, distress and erection quality, and give the clinician the full medicines list.
- Arrange the first benefit-risk review specified in the label: after four weeks or at least six treatment occasions, with ongoing review at least every six months.
Don’t:
- Add dapoxetine to antidepressants or erection medicines yourself, or drink alcohol with it.
- Judge success against an arbitrary stopwatch target; the trial also assessed control, distress and the patient’s own rating.